Browse > Article
http://dx.doi.org/10.4333/KPS.2011.41.5.289

Pharmacokinetic Analysis of Montelukast in Healthy Korean Volunteers by High Performance Liquid Chromatography-Tandem Mass Spectrometry  

Jo, Min-Ho (College of Pharmacy, Kyung Hee University)
Park, Mi-Sun (College of Pharmacy, Kyung Hee University)
Seo, Ji-Hyung (College of Pharmacy, Kyung Hee University)
Shim, Wang-Seob (College of Pharmacy, Kyung Hee University)
Yim, Sung-Vin (College of Medicine, Kyung Hee University)
Lee, Kyung-Tae (College of Pharmacy, Kyung Hee University)
Publication Information
Journal of Pharmaceutical Investigation / v.41, no.5, 2011 , pp. 289-294 More about this Journal
Abstract
A rapid and specific high performance liquid chromatography-tandem mass (LC/MS/MS) method for the analysis of montelukast in human plasma has been developed and validated. After cold acetonitrile-induced precipitation of the plasma samples, montelukast and glipizide (internal standard, IS) were eluted on a reverse-phase $C_{18}$ column by isocratic mobile phase consisted of 10 mM ammonium formate buffer (adjusted to pH 3.5 with formic acid) and acetonitrile (3:97, v/v). Acquisition was performed with multiple reaction monitoring (MRM) mode by monitoring the transitions: m/z 587.2${\rightarrow}$ 423.2 for montelukast and m/z 446.0${\rightarrow}$321.2 for IS. Ranges of concentration for calibration curves (10-1000 ng/mL) showed correlation coefficients ($r^2$) were better than 0.9948. Precision of intra- and inter-day ranged from 3.70 to 11.68% and from 3.04 to 12.95%, accuracy of intra-day and inter-day ranged from 93.34 to 102.75% and from 100.79 to 107.63%, respectively. The described method provides a fast and sensitive analytical tool for determining montelukast levels in plasma, and was successfully applied to a pharmacokinetic study in 16 healthy human subjects after oral administration of 10mg tablet formulation of montelukast sodium under fasting conditions.
Keywords
Montelukast; Pharmacokinetic study; Human plasma; LC/MS/MS; Korean;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Al-Rawithi, S., Al-Gazlan, S., Al-Ahmadi, W., Alshowaier, IA., Yusuf, A., Raines, D.A., 2011. Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. J Chromatogr B Biomed Sci. 754(2), 527-531.
2 Smith, G.A., Rawls, C.M., Kunka, R.L., 2004. An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product. Pharm Res. 21(9), 1539-1544.   DOI
3 Bharathi, D.V., Hotha, K.K., Jagadeesh, B., Mullangi, R., Naidu, A., 2009. Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. Biomed Chromatogr. 23(8), 804-810.   DOI
4 Cheng, H., Leff, J.A., Amin, R., Gertz, B.J., De Smet, M., Noonan, N., Rogers, J.D., Malbecq, W., Meisner, D. Somers, G., 1996. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharmaceutical Research. 13, 445-448.   DOI
5 Ochiai, H., Uchiyama, N., Takano, T., Hara, K., Kamei, T., 1998. Determination of montelukast sodium in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 713(2), 409-414.   DOI
6 Alsarra, I., Khalil, NY., Sultan, M., Al-Ashban, R., Belal, F., 2005. Spectrofluorometric determination of montelukast in dosage forms and spiked human plasma. Pharmazie. 60(11), 823-826.
7 Al Omari, M.M., Zoubi, R.M., Hasan, E.I., Khader, T.Z., Badwan, A.A., 2007. Effect of light and heat on the stability of montelukast in solution and in its solid state. J Pharm Biomed Anal. 45(3), 465-471.   DOI
8 Korea FDA, 2003 Guideline for the Validation of Bioanalytical Method 2003.05.
9 Challa, B.R., Awen B.Z., Chandu, B.R., Khagga, M., Kotthapalli, CB., 2010. Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/ MS: Application to a bioequivalence study. Sci Pharm. 78(3), 411-422.   DOI
10 Sripalakit, P., Kongthong, B., Saraphanchotiwitthaya, A., 2008. A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 869(1-2), 38-44.   DOI
11 Mastalerz, L., Kumik, J., 2010. Antileukotriene drugs in the treatment of asthma. Pol Arch Med Wewn. 120(3), 103-108.
12 Castro-Rodriguez, J.A., Rodrigo, G.J., 2010. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 95(5), 365-370.   DOI
13 Yasar, H., Kiran, B., Cagatay, T., Ozkul, H., Icten, S., 2011. The effect of montelukast sodium on serum arginase levels in patients with seasonal allergic rhinitis. Am J Rhinol Allergy.
14 Schaper, C., Noga, O., Koch, B., Ewert, R., Felix, S.B., Gläser S., Kunkel, G., Gustavus B., 2011. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 21(1), 51-58.
15 Liu, L., Cheng, H., Zhao, J.J., Rogers, J.D., 1997. Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching. J Pharm Biomed Anal. 15(5), 631-638.   DOI
16 Amin, R.D., Cheng, H., Rogers, J.D., 1995. Determination of MK- 0476 in human plasma by liquid chromatography. J Pharm Biomed Anal. 13(2), 155-158.   DOI